Development of Therapeutics and Diagnostics for Biodefense Program

by: Michael Saunders

The National Institutes of Health, otherwise termed as NIH, is an agency operating within the United States Department of Health and Human Services that is generally responsible for financially supporting the country's biomedical and health-related research studies.

The initiatives of the NIH are all geared towards the realization its primary agency mission which is to "seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability."

In keeping with this mission, the National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

NIAID Category A, B, and C priority agents are pathogens that can be used as a biological weapon in acts of terrorism or sabotage. The examples of these pathogens are the ones that cause, anthrax, botulism, plague, smallpox, tularemia, hemorrhagic fevers, melioidosis, brucellosis, typhus fever, yellow fever, rabies, and several others.

The goal of the Development of Therapeutics and Diagnostics for Biodefense is to solicit applications from eligible participants in order to further explore the options and strategies that can lead to the treatment or diagnosis of the diseases that are mentioned above.

  (continued...)

Development of Therapeutics and Diagnostics for Biodefense Program
  Page 2

About The Author Michael Saunders is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. He also maintains Websites providing resources on artist grants and children grants.

Additional Resources

category - Health Grants

Minor Use Minor Species Development of Drugs: Research Project Grant
The National Institutes of Health has partnered with the U.S. Food and Drug Administration (FDA) and the Center for Veterinary Medicine(CVM) in an effort to establish the Minor Use Minor Species Development of Drugs: Research Project Grant.

---

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

---

Cancer Education Grants Program
The Cancer Education Grants Program has been existent since the year 1994 and has long been providing support to innovative cancer education grants program that aim to translate the knowledge obtain from the research studies into actual public health applications.

---

Early-Stage Innovative Technology Development for Cancer Research Program
The National Institutes of Health has collaborated with the National Cancer Institute(NCI) in order to establish Early-Stage Innovative Technology Development for Cancer Research Program, wherein both agencies intend to solicit grant applications expressing intents to conduct funded exploratory research projects that concentrate on the inception and development unique, innovative technological advances that could potentially be utilized in the study of cancer.

---